Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.0
(2.35%)
USD 10.0
(2.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.63 Billion USD | -180.39% |
| 2023 | -3.08 Billion USD | -171.02% |
| 2022 | 4.33 Billion USD | 70.61% |
| 2021 | 2.54 Billion USD | 457.46% |
| 2020 | 456 Million USD | -88.55% |
| 2019 | 3.98 Billion USD | -20.74% |
| 2018 | 5.02 Billion USD | 23.2% |
| 2017 | 4.07 Billion USD | -2.28% |
| 2016 | 4.17 Billion USD | -1.11% |
| 2015 | 4.22 Billion USD | 118.43% |
| 2014 | 1.93 Billion USD | -24.18% |
| 2013 | 2.54 Billion USD | 19.79% |
| 2012 | 2.12 Billion USD | -21.63% |
| 2011 | 2.71 Billion USD | 29.79% |
| 2010 | 2.09 Billion USD | 4.24% |
| 2009 | 2 Billion USD | -6.99% |
| 2008 | 2.15 Billion USD | 5.65% |
| 2007 | 2.04 Billion USD | 16.61% |
| 2006 | 1.75 Billion USD | 12.25% |
| 2005 | 1.55 Billion USD | 14.65% |
| 2004 | 1.36 Billion USD | 15.69% |
| 2003 | 1.17 Billion USD | 15.36% |
| 2002 | 1.01 Billion USD | 15.09% |
| 2001 | 885.6 Million USD | 13.99% |
| 2000 | 776.9 Million USD | 24.48% |
| 1999 | 624.1 Million USD | 22.13% |
| 1998 | 511 Million USD | 17.2% |
| 1997 | 436 Million USD | 17.3% |
| 1996 | 371.7 Million USD | 15.87% |
| 1995 | 320.8 Million USD | 13.8% |
| 1994 | 281.9 Million USD | 27.15% |
| 1993 | 221.7 Million USD | 0.5% |
| 1992 | 220.6 Million USD | 13.13% |
| 1991 | 195 Million USD | 11.68% |
| 1990 | 174.6 Million USD | 13.23% |
| 1989 | 154.2 Million USD | 19.44% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.9 Billion USD | -8717.91% |
| 2024 Q1 | -67 Million USD | 62.78% |
| 2024 Q3 | 344 Million USD | 105.82% |
| 2024 Q4 | -3 Billion USD | -973.55% |
| 2023 Q2 | 703 Million USD | 118.89% |
| 2023 Q4 | -180 Million USD | -252.54% |
| 2023 Q1 | -3.72 Billion USD | -796.63% |
| 2023 FY | -3.08 Billion USD | -171.02% |
| 2023 Q3 | 118 Million USD | -83.21% |
| 2022 Q4 | -415 Million USD | -243.6% |
| 2022 Q1 | 3.58 Billion USD | 470.97% |
| 2022 FY | 4.33 Billion USD | 226.58% |
| 2022 Q3 | 289 Million USD | -67.27% |
| 2022 Q2 | 883 Million USD | -75.34% |
| 2021 FY | 1.32 Billion USD | 191.23% |
| 2021 Q1 | -308 Million USD | -182.57% |
| 2021 Q2 | 1.02 Billion USD | 433.12% |
| 2021 Q3 | 1.19 Billion USD | 16.67% |
| 2021 Q4 | 627 Million USD | -47.62% |
| 2020 Q4 | 373 Million USD | 121.84% |
| 2020 FY | 456 Million USD | -88.55% |
| 2020 Q1 | 845 Million USD | 24.82% |
| 2020 Q2 | 946 Million USD | 11.95% |
| 2020 Q3 | -1.7 Billion USD | -280.55% |
| 2019 Q3 | 1.02 Billion USD | -11.33% |
| 2019 FY | 3.98 Billion USD | -20.74% |
| 2019 Q2 | 1.15 Billion USD | 2.94% |
| 2019 Q1 | 1.12 Billion USD | -25.73% |
| 2019 Q4 | 677 Million USD | -33.95% |
| 2018 Q2 | 1.34 Billion USD | 64.31% |
| 2018 FY | 5.02 Billion USD | 23.2% |
| 2018 Q1 | 821 Million USD | 2.37% |
| 2018 Q3 | 1.34 Billion USD | -0.52% |
| 2018 Q4 | 1.51 Billion USD | 12.67% |
| 2017 Q4 | 802 Million USD | -30.98% |
| 2017 Q2 | 1.06 Billion USD | 0.57% |
| 2017 Q1 | 1.05 Billion USD | 2.33% |
| 2017 Q3 | 1.16 Billion USD | 9.62% |
| 2017 FY | 4.07 Billion USD | -2.28% |
| 2016 Q1 | 1.11 Billion USD | 4169.23% |
| 2016 Q2 | 930 Million USD | -16.22% |
| 2016 Q4 | 1.03 Billion USD | -6.62% |
| 2016 FY | 4.17 Billion USD | -1.11% |
| 2016 Q3 | 1.1 Billion USD | 18.6% |
| 2015 FY | 4.22 Billion USD | 118.43% |
| 2015 Q4 | 26 Million USD | -98.0% |
| 2015 Q3 | 1.3 Billion USD | -36.24% |
| 2015 Q2 | 2.04 Billion USD | 140.24% |
| 2015 Q1 | 850 Million USD | 484.62% |
| 2014 FY | 1.93 Billion USD | -21.14% |
| 2014 Q1 | 723 Million USD | 10.05% |
| 2014 Q2 | 716 Million USD | -0.97% |
| 2014 Q4 | -221 Million USD | -130.95% |
| 2014 Q3 | 714 Million USD | -0.28% |
| 2013 FY | 2.45 Billion USD | 15.19% |
| 2013 Q3 | 624 Million USD | -17.46% |
| 2013 Q1 | 413 Million USD | 17.0% |
| 2013 Q2 | 756 Million USD | 83.05% |
| 2013 Q4 | 657 Million USD | 5.29% |
| 2012 Q4 | 353 Million USD | -34.26% |
| 2012 Q1 | 554 Million USD | -30.05% |
| 2012 Q3 | 537 Million USD | -21.38% |
| 2012 Q2 | 683 Million USD | 23.29% |
| 2012 FY | 2.12 Billion USD | -21.63% |
| 2011 Q2 | 739 Million USD | 27.41% |
| 2011 FY | 2.71 Billion USD | 29.79% |
| 2011 Q4 | 792 Million USD | 31.34% |
| 2011 Q3 | 603 Million USD | -18.4% |
| 2011 Q1 | 580 Million USD | 23.4% |
| 2010 Q4 | 470 Million USD | 1.51% |
| 2010 FY | 2.09 Billion USD | 4.24% |
| 2010 Q3 | 463 Million USD | -30.79% |
| 2010 Q2 | 669 Million USD | 36.81% |
| 2010 Q1 | 489 Million USD | 12.16% |
| 2009 Q2 | 640 Million USD | 56.86% |
| 2009 Q3 | 522 Million USD | -18.44% |
| 2009 Q4 | 436 Million USD | -16.48% |
| 2009 FY | 2 Billion USD | -6.99% |
| 2009 Q1 | 408 Million USD | -7.9% |
| 2008 Q1 | 455.5 Million USD | 14.88% |
| 2008 FY | 2.15 Billion USD | 5.65% |
| 2008 Q3 | 572.3 Million USD | -16.56% |
| 2008 Q4 | 443 Million USD | -22.59% |
| 2008 Q2 | 685.9 Million USD | 50.58% |
| 2007 Q4 | 396.5 Million USD | -29.35% |
| 2007 Q2 | 651.9 Million USD | 51.01% |
| 2007 FY | 2.04 Billion USD | 16.61% |
| 2007 Q3 | 561.2 Million USD | -13.91% |
| 2007 Q1 | 431.7 Million USD | 4.71% |
| 2006 Q3 | 469.2 Million USD | -10.37% |
| 2006 FY | 1.75 Billion USD | 12.25% |
| 2006 Q1 | 345.6 Million USD | 5.05% |
| 2006 Q2 | 523.5 Million USD | 51.48% |
| 2006 Q4 | 412.3 Million USD | -12.13% |
| 2005 Q2 | 490.9 Million USD | 47.55% |
| 2005 Q1 | 332.7 Million USD | 1.68% |
| 2005 Q3 | 411 Million USD | -16.28% |
| 2005 Q4 | 329 Million USD | -19.95% |
| 2005 FY | 1.55 Billion USD | 14.65% |
| 2004 FY | 1.36 Billion USD | 15.69% |
| 2004 Q2 | 433.5 Million USD | 70.07% |
| 2004 Q3 | 344.6 Million USD | -20.51% |
| 2004 Q4 | 327.2 Million USD | -5.05% |
| 2004 Q1 | 254.9 Million USD | -8.01% |
| 2003 Q1 | 231.6 Million USD | -6.5% |
| 2003 Q4 | 277.1 Million USD | -6.42% |
| 2003 Q3 | 296.1 Million USD | -20.17% |
| 2003 Q2 | 370.9 Million USD | 60.15% |
| 2003 FY | 1.17 Billion USD | 15.36% |
| 2002 Q3 | 259 Million USD | -20.7% |
| 2002 Q4 | 247.7 Million USD | -4.36% |
| 2002 Q2 | 326.6 Million USD | 75.69% |
| 2002 Q1 | 185.9 Million USD | -14.29% |
| 2002 FY | 1.01 Billion USD | 15.09% |
| 2001 Q4 | 216.9 Million USD | 1.64% |
| 2001 FY | 885.6 Million USD | 13.99% |
| 2001 Q3 | 213.4 Million USD | -28.12% |
| 2001 Q2 | 296.9 Million USD | 87.44% |
| 2001 Q1 | 158.4 Million USD | -26.87% |
| 2000 Q4 | 216.6 Million USD | 11.88% |
| 2000 Q2 | 238.9 Million USD | 86.93% |
| 2000 Q3 | 193.6 Million USD | -18.96% |
| 2000 Q1 | 127.8 Million USD | -20.42% |
| 2000 FY | 776.9 Million USD | 24.48% |
| 1999 Q4 | 160.6 Million USD | 0.82% |
| 1999 Q1 | 104 Million USD | -31.58% |
| 1999 FY | 624.1 Million USD | 22.13% |
| 1999 Q2 | 200.2 Million USD | 92.5% |
| 1999 Q3 | 159.3 Million USD | -20.43% |
| 1998 Q4 | 152 Million USD | 19.69% |
| 1998 Q2 | 171 Million USD | 180.33% |
| 1998 Q3 | 127 Million USD | -25.73% |
| 1998 Q1 | 61 Million USD | -42.13% |
| 1998 FY | 511 Million USD | 17.2% |
| 1997 Q2 | 147.4 Million USD | 96.53% |
| 1997 Q4 | 105.4 Million USD | -2.5% |
| 1997 FY | 436 Million USD | 17.3% |
| 1997 Q1 | 75 Million USD | -16.39% |
| 1997 Q3 | 108.1 Million USD | -26.66% |
| 1996 Q3 | 91.6 Million USD | -27.76% |
| 1996 FY | 371.7 Million USD | 15.87% |
| 1996 Q1 | 63.7 Million USD | -16.51% |
| 1996 Q2 | 126.8 Million USD | 99.06% |
| 1996 Q4 | 89.7 Million USD | -2.07% |
| 1995 Q1 | 54 Million USD | -21.85% |
| 1995 Q4 | 76.3 Million USD | -3.42% |
| 1995 Q3 | 79 Million USD | -29.21% |
| 1995 Q2 | 111.6 Million USD | 106.67% |
| 1995 FY | 320.8 Million USD | 13.8% |
| 1994 FY | 281.9 Million USD | 27.15% |
| 1994 Q1 | 44.2 Million USD | 34.76% |
| 1994 Q4 | 69.1 Million USD | -2.68% |
| 1994 Q3 | 71 Million USD | -27.25% |
| 1994 Q2 | 97.6 Million USD | 120.81% |
| 1993 Q3 | 64.4 Million USD | -23.52% |
| 1993 Q4 | 32.8 Million USD | -49.07% |
| 1993 Q2 | 84.2 Million USD | 108.93% |
| 1993 Q1 | 40.3 Million USD | -21.6% |
| 1993 FY | 221.7 Million USD | 0.5% |
| 1992 Q1 | 35.4 Million USD | -23.21% |
| 1992 Q4 | 51.4 Million USD | -9.19% |
| 1992 FY | 220.6 Million USD | 13.13% |
| 1992 Q2 | 77.1 Million USD | 117.8% |
| 1992 Q3 | 56.6 Million USD | -26.59% |
| 1991 Q4 | 46.1 Million USD | -6.49% |
| 1991 Q1 | 32.1 Million USD | -20.54% |
| 1991 Q2 | 67.5 Million USD | 110.28% |
| 1991 FY | 195 Million USD | 11.68% |
| 1991 Q3 | 49.3 Million USD | -26.96% |
| 1990 Q3 | 43.6 Million USD | -29.56% |
| 1990 Q1 | 28.7 Million USD | 0.0% |
| 1990 FY | 174.6 Million USD | 13.23% |
| 1990 Q2 | 61.9 Million USD | 115.68% |
| 1990 Q4 | 40.4 Million USD | -7.34% |
| 1989 FY | 154.2 Million USD | 19.44% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -5536.377% |
| Dynavax Technologies Corporation | -6.38 Million USD | -135069.823% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 656331.003% |
| Perrigo Company plc | -12.7 Million USD | -67900.0% |
| Illumina, Inc. | -1.16 Billion USD | -643.842% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 244.053% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -1844.883% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 735.935% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -7711.214% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 318.434% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -21565.83% |
| Waters Corporation | 642.23 Million USD | 1444.681% |
| Biogen Inc. | 1.16 Billion USD | 843.777% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -3249.481% |
| Evolus, Inc. | -61.68 Million USD | -13900.162% |
| Adicet Bio, Inc. | -142.65 Million USD | -5953.639% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -7186.964% |
| bluebird bio, Inc. | -211.91 Million USD | -3975.257% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -4027.16% |
| FibroGen, Inc. | -284.23 Million USD | -2938.363% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 796.452% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -19261.789% |
| Homology Medicines, Inc. | -53.74 Million USD | -15969.069% |
| Geron Corporation | -184.12 Million USD | -4590.241% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -1861.648% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -5597.171% |
| Myriad Genetics, Inc. | -112 Million USD | -7610.714% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -9954.136% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -1694.71% |
| Zoetis Inc. | 2.34 Billion USD | 468.43% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -15837.108% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 1194.858% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 5251.362% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 338.59% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -20364.94% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -2257.72% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -3027.558% |
| Verastem, Inc. | -87.36 Million USD | -9784.739% |
| Nektar Therapeutics | -276.05 Million USD | -3028.351% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -3509.794% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -9660.288% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | -1511.263% |
| OPKO Health, Inc. | -188.86 Million USD | -4472.627% |
| Exelixis, Inc. | 207.76 Million USD | 4256.619% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 3558.55% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 8236.424% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -18079.139% |
| uniQure N.V. | -308.47 Million USD | -2699.551% |
| Imunon, Inc. | -19.51 Million USD | -44153.191% |
| Blueprint Medicines Corporation | -506.98 Million USD | -1603.407% |
| Insmed Incorporated | -749.56 Million USD | -1052.132% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 3166.827% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -2352.796% |
| TG Therapeutics, Inc. | 12.67 Million USD | 68250.253% |
| Incyte Corporation | 597.59 Million USD | 1545.116% |
| Emergent BioSolutions Inc. | -760.5 Million USD | -1035.569% |